tradmap

MDCX Earnings Medicus Pharma Ltd.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$137 -$69 $0 2023 2024 2025
EPS
Net income (annual)
-$47M -$24M $0 2023 2024 2025
Net income
Return on equity (annual)
-356% 34817% 69991% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$56 -$28 $0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$21M -$10M $0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-682% 10811% 22304% 0% Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–13 of 13
Q2 20262026-06-30-10.502026-08-1210-Q
Q1 20262026-03-31-15.502026-05-1410-Q
Q4 2025 (derived)2025-12-31-38.502026-03-2510-K
FY 20252025-12-31-137.002026-03-2510-K
Q3 20252025-09-30-56.002025-11-1410-Q
Q2 20252025-06-30-21.502025-08-1110-Q
Q1 20252025-03-31-21.002025-05-1210-Q
Q4 2024 (derived)2024-12-31-13.502025-03-2810-K
FY 20242024-12-31-58.002025-03-2810-K
Q3 20242024-09-30-12.00——
Q2 20242024-06-30-22.00——
Q1 20242024-03-31-10.50——
FY 20232023-12-31-76.50——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.